Regulus Therapeutics Inc. (Nasdaq: RGLS) received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE